对Palbociclib Plus Lenvatinib作为CDKN2A/2B删除肝脏内胆固醇癌的二线治疗的显著反应:一个病例报告

相关实验视频

Updated: May 29, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Kai Liu1,2, Ziyue Huang2, Lijin Zhao1

  • 1Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.

Journal of clinical and translational hepatology
|February 7, 2025
PubMed
概括

一名患有CDKN2A/2B删除的胆道癌症患者在Palbociclib和Lenvatinib的治疗中显示出瘤回归. 这种无化疗方案为这种特定的基因变异提供了一个有前途的二线治疗选择.

关键词:
案例报告案例报告胆性瘤是一种胆性瘤.循环素依赖性激酶抑制剂 2A/2B 删除循环素依赖性激酶4/6抑制剂在Palbocicliblib中使用.

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K